Hepatitis Test Solution Diagnosis Market Research Report - Global Forecast till 2027

Global Hepatitis Test Solution Diagnosis Market Research Report: Information by Disease Type (Hepatitis A, Hepatitis B, Hepatitis C  and others), Type of Technology [Nucleic Acid Testing (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Diagnostic Tests (RDT), Chemiluminescence Immunoassay (CLIA), Genotyping and others], End User (Hospitals, Clinics, Diagnostic Laboratories, Blood Banks, Research Institutes and others) and Region (the Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2027

ID: MRFR/HC/6012-HCR | February 2021 | Region: Global | 110 pages

Please note that the assessment period of report has been updated from 2019-2025 to 2020-2027. Cordially fill the sample form for updated data.

Market Scenario


Hepatitis Test Solution Diagnosis Market is expected to grow significantly over the forecast period. It is anticipated that the market held a value of USD 2,659.38 Million in 2018 and is projected to register a 4.4% CAGR over the forecast period.


Globally, there are approximately 71 million individuals that are chronically infected with the hepatitis C virus (HCV). The increasing participation of the regulatory agencies and health care associations towards the testing/diagnosis and treatments of the hepatitis is driving the global market. In 2018, the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America, published a guideline for testing, managing, and treating hepatitis C. Various other factors such as the rise prevalence hepatitis, increasing geriatric population, rise in regulatory approvals, and growing participation of generic drugs manufacturers are boosting the market growth.


However, complicated testing and diagnosis process and the side-effects of medication may hamper market growth over the forecast period.


Segmentation


Global Hepatitis Test Solution Diagnosis Market is segmented based on disease type, type of technology, end user, and region.


Based on disease type, the global hepatitis test solution diagnosis market is further segmented into hepatitis A, hepatitis B, hepatitis C, and others.


Based on the type of technology, the hepatitis test solution diagnosis market at the global level is segmented into nucleic acid testing (NAT), enzyme-linked immunosorbent assay (ELISA), rapid diagnostic tests (RDT), chemiluminescence immunoassay (CLIA), genotyping, and others.


Based on end-user, the global market is segmented into hospitals, clinics, diagnostic laboratories, blood banks, research institutes, and others


The segments mentioned above are covered under four regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East & Africa.


The hepatitis test solution diagnosis market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European hepatitis test solution diagnosis market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified into Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The hepatitis test solution diagnosis market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The hepatitis test solution diagnosis market in the Middle East & Africa has been segmented into the Middle East and Africa.


Regional Market Summary


Global Hepatitis Test Solution Diagnosis Market Share (%), by Region, 2018  Hepatitis Test Solution Diagnosis Market


Sources: MRFR Analysis


The Americas dominated the hepatitis test solution diagnosis market, owing to the increasing number of patients that are diagnosed with hepatitis, annually. In the Latin America and Caribbean countries, currently, around 9 million people are anti-hepatitis C virus (HCV) positive.


Europe is expected to be the second-largest region in the hepatitis test solution diagnosis market, owing to the growing detection of hepatitis virus cases in the region.


The market in Asia-Pacific (APAC) is expected to grow significantly owing to the rising prevalence of hepatitis genotypes. Various clinical studies are being carried out. For instance, studies related to the Genotype 1b were done to understand the body’s response to the hepatitis virus.


Thus, the hepatitis test solution diagnosis market in APAC is expected to hold the third-largest share during the forecast period.


The Middle East & Africa is expected to hold the least share of the hepatitis test solution diagnosis market during the forecast due to the slow economic development, especially in Africa.


Key Players


Some of the Key Players operating in the Global Hepatitis Test Solution Diagnosis Market are Abbott, Biomérieux Sa, Bio-Rad Laboratories, Inc., Danaher, DiaSorin S.p.A., Miraca Holdings Inc. (Fujirebio, Inc.), Grifols, Onsite Lab Holding AG (MedMira, Inc.), Qiagen, Roche Holding AG (Roche Diagnostics), Siemens (Siemens Healthineers), and Sandoz International GmbH.


Market Segmentation


Global Hepatitis Test Solution Diagnosis Market, by Disease Type



  • Hepatitis A

  • Hepatitis B

  • Hepatitis C

  • Others


Global Hepatitis Test Solution Diagnosis Market, by Type of Technology



  • Nucleic Acid Testing (NAT)

  • Enzyme-Linked Immunosorbent Assay (ELISA)

  • Rapid Diagnostic Tests (RDT)

  • Chemiluminescence Immunoassay (CLIA)

  • Genotyping

  • Others


Global Hepatitis Test Solution Diagnosis Market, by End User



  • Hospitals

  • Diagnostic Laboratories

  • Blood Banks

  • Research institutes

  • Others


Intended Audience



  • Pharmaceutical companies

  • Government and private laboratories

  • Research and development (R&D) companies

  • Research laboratories

  • Market research and consulting service providers



Report Scope:
Report Attribute/Metric Details
  Market Size   USD 2,659.38 Million (2025)
  CAGR   4.4% (2019-2025)
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Disease Type, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Abbott, Biomérieux Sa, Bio-Rad Laboratories, Inc., Danaher, DiaSorin S.p.A., Miraca Holdings Inc. (Fujirebio, Inc.), Grifols, Onsite Lab Holding AG (MedMira, Inc.), Qiagen, Roche Holding AG (Roche Diagnostics), Siemens (Siemens Healthineers), and Sandoz International GmbH.
  Key Market Opportunities

  • The rise prevalence hepatitis.
  • Increasing Geriatric Population.
  • Growing participation of generic drugs manufacturers.
  •   Key Market Drivers

  • The increasing participation of the regulatory agencies.
  • Health Care associations towards the testing


  • Frequently Asked Questions (FAQ) :


    The market was valued at more than USD 2.6 billion in 2018.

    The market is expected to exhibit a strong 4.4% CAGR over the forecast period from 2019 to 2025.

    The rise in the prevalence of hepatitis is likely to be the major driver for the market.

    The Americas hold a dominant share in the global market of more than 45%.

    Leading players in the market include Abbott, Miraca, Danaher, and Roche, among others.



    This table of content is tentative and subject to change as the research progresses.

    Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.